

6 August 2025

Melissa Kostopoulos  
Listing Compliance Advisor  
ASX Compliance Pty Ltd  
525 Collins Street  
North Tower Level 4  
MELBOURNE VIC 3000

By email: [ListingsComplianceMelbourne@asx.com.au](mailto:ListingsComplianceMelbourne@asx.com.au)

Dear Melissa

**Rhythm Biosciences Limited ('RHY') – Response to ASX Price Query**

We refer to your letter of 6 August 2025 (Reference: ODIN111470) and provide the following responses to your questions:

1. ***Is RHY aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?***

Answer – No

2. ***If the answer to question 1 is "yes".***

- a) ***Is RHY relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in RHY's securities would suggest to ASX that such information may have ceased to be confidential and therefore RHY may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.***
- b) ***Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).***
- c) ***If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?***

Answer – NA

3. ***If the answer to question 1 is "no", is there any other explanation that RHY may have for the recent trading in its securities?***

Answer - No

4. ***Please confirm that RHY is complying with the Listing Rules and, in particular, Listing Rule 3.1***

Answer – Yes

5. Please confirm that RHY's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of RHY with delegated authority from the board to respond to ASX on disclosure matters.

Answer - Yes

- ENDS -

#### Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com) or on +61 3 8256 2880:

<b>Mr Otto Buttula</b> Chairman	<b>Mr Mark Licciardo</b> Company Secretary
------------------------------------	---

#### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

#### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

#### About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).



6 August 2025

Reference: ODIN111470

Mr Mark Licciardo  
Company Secretary  
Rhythm Biosciences Limited  
Bio21 Institute  
30 Flemington Road  
Parkville, Vic 3010

By email: m.licciardo@acclime.com

Dear Mr Licciardo

**Rhythm Biosciences Limited ('RHY'): Price - Query**

ASX refers to the following:

- A. The change in the price of RHY's securities from a low of \$0.095 at close of trade yesterday to a high of \$0.21 today.
- B. The significant increase in the volume of RHY's securities traded today.

**Request for information**

In light of this, ASX asks RHY to respond separately to each of the following questions and requests for information:

1. Is RHY aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is RHY relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in RHY's securities would suggest to ASX that such information may have ceased to be confidential and therefore RHY may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that RHY may have for the recent trading in its securities?
4. Please confirm that RHY is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that RHY's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of RHY with delegated authority from the board to respond to ASX on disclosure matters.

For personal use only

---

### When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **2:30 PM AEST Wednesday, 6 August 2025**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, RHY's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require RHY to request a trading halt immediately.

Your response should be sent to me by e-mail at [ListingsComplianceMelbourne@asx.com.au](mailto:ListingsComplianceMelbourne@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in RHY's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in RHY's securities under Listing Rule 17.3.

### Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to RHY's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that RHY's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Regards

---

ASX Compliance